Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Evoke Pharma, Inc. (EVOK : NSDQ)
 
 • Company Description   
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.69 Daily Weekly Monthly
20 Day Moving Average: 235,299 shares
Shares Outstanding: 1.56 (millions)
Market Capitalization: $16.66 (millions)
Beta: -0.14
52 Week High: $10.79
52 Week Low: $1.94
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 132.90% 126.80%
12 Week 108.79% 100.13%
Year To Date 141.85% 111.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
420 STEVENS AVENUE SUITE 230
-
SOLANA BEACH,CA 92075
USA		 ph: 858-345-1494
fax: -		 dboateng@dkbpartners.net http://www.evokepharma.com
 
 • General Corporate Information   
Officers
Matthew J. D'Onofrio - Chief Executive Officer
Cam L. Garner - Chairman
Mark Kowieski - Chief Financial Officer
Todd C. Brady - Director
Vickie W. Reed - Director

Peer Information
Evoke Pharma, Inc. (BGMR)
Evoke Pharma, Inc. (BBIO)
Evoke Pharma, Inc. (IPAH)
Evoke Pharma, Inc. (BRL)
Evoke Pharma, Inc. (BHC)
Evoke Pharma, Inc. (AKRXQ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-GENERIC DRG
Sector: Medical
CUSIP: 30049G302
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/06/25
Share - Related Items
Shares Outstanding: 1.56
Most Recent Split Date: 8.00 (0.08:1)
Beta: -0.14
Market Capitalization: $16.66 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.65
Price/Cash Flow: -
Price / Sales: 1.30
EPS Growth
vs. Year Ago Period: 33.33%
vs. Previous Quarter: -21.57%
Sales Growth
vs. Year Ago Period: 47.08%
vs. Previous Quarter: 21.82%
ROE
09/30/25 - -
06/30/25 - -99.48
03/31/25 - -101.91
ROA
09/30/25 - -
06/30/25 - -33.58
03/31/25 - -33.75
Current Ratio
09/30/25 - -
06/30/25 - 1.37
03/31/25 - 1.55
Quick Ratio
09/30/25 - -
06/30/25 - 1.32
03/31/25 - 1.50
Operating Margin
09/30/25 - -
06/30/25 - -42.07
03/31/25 - -43.80
Net Margin
09/30/25 - -
06/30/25 - -42.07
03/31/25 - -43.80
Pre-Tax Margin
09/30/25 - -
06/30/25 - -42.07
03/31/25 - -43.80
Book Value
09/30/25 - -
06/30/25 - 2.93
03/31/25 - 3.91
Inventory Turnover
09/30/25 - -
06/30/25 - 0.82
03/31/25 - 0.61
Debt-to-Equity
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©